Bioconjugation Market – Global Forecast to 2029
The bioconjugation market is expected to grow to USD 10.86 billion by 2029, up from USD 5.27 billion in 2024, at a CAGR of 15.6% between 2024 and 2029.
バイオコンジュゲーション市場は、2024年の52億7,000万米ドルから2029年までに108億6,000万米ドルに成長し、2024年から2029年までのCAGRは15.6%と予想されています。
Danaher Corporation (US); Lonza (Switzerland); Thermo Fisher Scientific Inc. (US); Merck KGaA (Germany); AbbVie Inc. (US); WuXi Biologics (Cayman) Inc. (China); Sartorius AG (Germany); are some of the key players in the bioconjugation market.
The report provides insights on the following pointers:
- Analysis of key drivers (growing demand for targeted therapies, increasing investments in biopharmaceutical R&D, rising demand for outsourcing services, expanding pipeline of bioconjugated drugs, advancements in bioconjugation technologies), restraints (high cost of bioconjugate development & manufacturing, stringent regulatory requirements), opportunities (high growth potential of emerging economies, expanding applications of bioconjugation), and Challenges (technical complexities) influencing the growth of the market.
- Product/Service Development/Innovation: Detailed insights on newly launched products/services of the bioconjugation market
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bioconjugation market
Competitive Assessment: In-depth assessment of market shares, growth strategies and product/service offerings of leading players like Danaher Corporation (US), Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), AbbVie Inc. (US), WuXi Biologics (Cayman) Inc. (China), Sartorius AG (Germany), Bio-Rad Laboratories, Inc. (US), among others in the market.